| abstract |
It is intended to provide a medicinal composition for inhibiting the expression of ATP-citrate lyase which contains a compound inhibiting the expression of ATP-citrate lyase when administered into the living body. Examples of the compound inhibiting the expression of ATP-citrate lyase when administered into the living body include insulin secretion accelerators such as nateglinide. This medicinal composition is efficacious in preventing, ameliorating and treating metabolic syndromes, in particular, liver disorders relative to lipid metabolic errors such as fatty liver and NASH. |